Loading...
 
Back to the list
Mediterr J Rheumatol 2022;33(1):68-74
Article Links
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
Eleftherios Pelechas, Vassiliki Drossou, Paraskevi V. Voulgari, Alexandros A. Drosos
Authors Information

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

E Pelechas, V Drossou, PV Voulgari, AA Drosos

Keywords: COVID-19, rheumatoid arthritis, hydroxychloroquine, tocilizumab, csDMARDs, bDMARDs
References
  1. Zhou F, Y T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62.
  2. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395(10228)e52.
  3. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762-8.
  4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4.
  5. Davison A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345(5):340-50.
  6. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88.
  7. Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88.
  8. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020;39(7):2055-62.
  9. Recommendations regarding COVID 19 infection in Rheumatic patients in Greece – The Greek Rheumatology Society and Professional Association of Rheumatologists – ERE-EPERE. Mediterr J Rheumatol 2020;31(1):6-7.
  10. European League against Rheumatism. EULAR.org/eular_guidance_for patients_covid19_outbreak.cfm. Accessed on 05 January 2020.
  11. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the management of Rheumatic Disease in Adult patients during the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020;72:1241-51.
  12. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region – case series. N Engl J Med 2020;382(21):2012-22.
  13. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020;38(2):175-80.
  14. Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2): What is the evidence? Mediterr J Rheumatol 2020;31(Suppl 2):259-67.
  15. Gianfrancesco M, Hyrich KL, Al-adely S, Carmona L, Danil MI, Gossec L, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2020;79(7):859-66.
  16. Haberman R, Axelrad J. Covid-19 in immune-mediated inflammatory diseases. Case series from New York. N Engl J Med 2020:NEJMc2009567.
  17. Haberman RH, Castillo R, Chn A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol 2020;72(12):1981-9.
  18. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Maihe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949.
  19. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020:ciaa237.
  20. Virdis A, Tani C, Duranti E, Vagnani S, Carli L, Kuhl AA, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Ther 2015;17:277.
  21. Xue H Liu Y, Luo P, Liu X, Qiu L, Liu D, et al. Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China. J Med Virol 2020;92:2523-7.
  22. Petri M, Konig MF, Li J, Goldman DW. Higher hydroxychloroquine blood levels are associated with reduced thrombosis risk in systemic lupus erythematosus. Arthritis Rheumatol 2021;73:997-1004.
  23. Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis 2020;79(10):1386-8.
  24. Putman M, Chock YPE, Tam H, Kim AHJ, Sattui E, Berenbaum F, et al. Antirheumatic Disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol 2021;73(1):36-47.
  25. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 2020;18(1):164.
  26. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020;117(20):10970-5.
  27. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92(7):814-8.
  28. Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol 2020;92(10):1787-8.
  29. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, de Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care 2020;58:29-33.
  30. Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab. Diagn Interv Imaging 2020;1010(5):323-4.
  31. Sciascia S, Apra F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicenter study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38(3):529-32.
  32. Campins L, Boixeda R, Perez-Cordon L, Aranega R, Lopera C, Force L. Early tocilizumab treatment could improve survival among COVID-19 patients. Clin Exp Rheumatol 2020;38(3):578.
  33. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112(10):3959-64.
  34. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2(6):e325-e331.
  35. Moutsopoulos HM. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Ann Rheum Dis 2020 Sep;79(9):1253-4.
  36. Roux CH, Brocq O, Gerald F, Pradier C, Bailly L. Clinical impact of COVID-19 on a French population of spondyloarthritis patients. Clin Rheumatol 2020;39(11):3185-3187. Doi: 10.1007/s10067-020-05413-9.
  37. Mihai C, Dobrota R, Schroder M, Garaiman A, Jordan S, Becker MO. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD, Ann Rheum Dis 2020;79:668-9.
  38. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020;79(6):837-9.
  39. Han Y, Jiang M, Xia D, He L, Lv X, Liao X, et al. COVID-19 in a patient with long-term use of glucocorticoids. A study of a familial cluster. Clin Immunol 2020;214:108413.
  40. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79(5):667-8.
  41. Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, et al. Coronavirus disase 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antireumatic drugs. Rheumatol Int 2020;40(6):991-5.
  42. Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. Ann Rheum Dis 2020;79(9):1251-2.
  43. Emmi G, Bettiol A, Mattioli I, Silvestri E, di Scla G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 2020;19(7):102575.
  44. Migkos MP, Kaltsonoudis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A, et al. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int 2021 Mar 3;1-7.
  45. Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol 2020;32(5):434-40.
  46. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021 Jul;80(7):930-42.
  47. Favalli EG, Ingegnoli F, de Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020;19(5):102523.
  48. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020;395(10223):e30-e31.
  49. Aitken T, Chin KL, Liew D, Ofori-Asenso R. Rethinking pandemic preparation: global health security index (GHSI) is predictive of COVID-19 burden, but in the opposite direction. J Infect 2020;81(2):318-56.
  50. Bower H, Frisell T, di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases an in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021;80(8):1086-93.
  51. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 2021;80(9):1137-46.
  52. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020;72(8):1241-51.
  53. Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf 2021;12:2042098620985687.